Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET

NCT02425865 is registered in ClinicalTrials.gov with Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives as lead sponsor.

NCT NCT02425865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02425865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Lead sponsor
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2016
Completion date
January 31, 2023
Enrollment
202 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis